We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis.
- Authors
Tatineni, Swetha; Warren, Zachary; Applebaum, Mark A.; Baroody, Fuad M.
- Abstract
Recurrent respiratory papillomatosis (RRP) is the most common benign pediatric laryngeal neoplasm. Various adjuvant medical therapies have failed to reliably decrease surgical frequency in this challenging airway disease. Recently, systemic bevacizumab has shown promise in advanced, treatment-resistant papillomatosis. We describe the use of systemic bevacizumab in two children with severe RRP unresponsive to other therapies. Voice and breathing improved dramatically in both patients with minimal side effects. Both patients have not required surgery in 24 months and 16 months, respectively. Systemic bevacizumab is a promising long-term treatment for severe RRP, with oncology playing an important role in patient care.
- Subjects
PAPILLOMAVIRUS diseases; BEVACIZUMAB
- Publication
Case Reports in Oncological Medicine, 2022, p1
- ISSN
2090-6706
- Publication type
Case Study
- DOI
10.1155/2022/2767996